Kristen Spencer, DO
Medical Oncology · New Brunswick, NJNPI 1720400906
Payments from drug & device makers
Across 593 payments — averaging $12,167 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2.6M
- Exelixis Inc.$1.5M
- Merck$664K
- Incyte Corporation$471K
- Eli Lilly$364K
- Boehringer Ingelheim International GmbH$325K
- plus $1.3M from 23 others
What the payments were for
- Consulting fees$38,13276%
- Speaking & faculty fees$4,80010%
- Travel & lodging$4,2769%
- Food & beverage$2,9616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $2,587,791 |
| Exelixis Inc. | 216 | $1,482,690 |
| Merck | 51 | $663,818 |
| Incyte Corporation | 103 | $471,105 |
| Eli Lilly | 10 | $363,776 |
| Boehringer Ingelheim International GmbH | 11 | $324,662 |
| Novartis | 5 | $285,760 |
| AstraZeneca | 19 | $224,485 |
| Boehringer Ingelheim | 6 | $197,740 |
| Jazz Pharmaceuticals Inc. | 10 | $97,790 |
| Daiichi Sankyo Inc. | 36 | $96,739 |
| Genentech, Inc. | 17 | $85,587 |
| E.r. Squibb & Sons, L.L.C. | 2 | $73,107 |
| AbbVie | 15 | $68,578 |
| Beigene, Ltd. | 14 | $64,078 |
| Beigene USA, Inc. | 17 | $51,968 |
| Beone Medicines Ltd. | 13 | $37,474 |
| Verastem, Inc. | 3 | $14,590 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $9,252 |
| Helsinn Therapeutics (U.S.), Inc. | 5 | $8,340 |
| Genentech USA, Inc. | 12 | $2,099 |
| Caris MPI, Inc. | 3 | $1,750 |
| Beone Medicines USA, Inc. | 4 | $1,182 |
| Foundation Medicine, Inc. | 1 | $229 |
| Array Biopharma Inc | 1 | $139 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Ipsen Biopharmaceuticals, Inc | 1 | $92 |
| GSK | 1 | $34 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$10,132
- ZIIHERA$9,064
- TRUSELTIQ$8,200
- IMFINZI$3,745
- Cabometyx$1,800
- MI CANCER SEEK$1,750
- Avastin$389
- FOUNDATIONONE CDX$229
- TECENTRIQ$150
- KRAZATI$109
How this compares
$7,214,975 in reported general payments places this provider in the 95th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New Brunswick
- Biren SaraiyaNew Brunswick$6.2M
- Sanjay GoelNew Brunswick$5.1M
- Mridula GeorgeNew Brunswick$4.5M
- Missak HaigentzNew Brunswick$3.9M
- Dale SchaarNew Brunswick$1.5M
- Sarah WeissNew Brunswick$1.5M
- Patrick BolandNew Brunswick$1.3M
- Roman GroisbergNew Brunswick$965K
- Tina MayerNew Brunswick$560K
- Kevin DavidNew Brunswick$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.